A. Boehler (Zurich, Switzerland), G. Snell (Melbourne, Australia)
Introduction: new therapeutic approaches to bronchiolitis obliterans G. Snell (Melbourne, Australia)
| |
Azithromycin (AZI) inhibits the IL-17 induced IL-8 production in human airway smooth muscle cells (HASMC): a possible explanation for the beneficial effect in BOS? B. M. Vanaudenaerde, W. A. Wuyts, L. J. Dupont, N. Geudens, M. G. Demedts, D. E. Van Raemdonck, G. M. Verleden (Leuven, Belgium)
| |
Hepatocyte growth factor (HGF) in lung allografts I. A. Forrest, C. Ward, D. M. Murphy, G. E. Johnson, A. J. Fisher, J. L. Lordan, P. A. Corris (Newcastle-upon-Tyne, United Kingdom)
| |
Possible role of CCL19, CCL20 and CCL22 in post transplant bronchiolitis obliterans F. Meloni, M. Morosini, N. Solari, A. Marone Bianco, I. Passadore, S. Miserere, C. Pellegrini, P. Vitulo, E. Pozzi, A. M. Fietta (Pavia, Italy)
| |
Extended measurement of exhaled nitric oxide in patients after lung transplantation M. Hofer, L. Mueller, C. Mahler, E. W. Russi, A. Boehler (Zurich, Switzerland)
| |
Gabexate mesilate attenuates ischemia-reperfusion injury of lung grafts via the inhibition of neutrophil activation M. Suga, T. Tsunoda, S. Yamazaki, T. Nakatani (Suita, Japan)
| |
The use of surfactant in severe reperfusion injury after lung transplantation A. Amital, D. Shitrit, D. Bendayan, Y. Raviv, M. R. Kramer (Petach Tikva, Israel)
| |
Increased recipient VEGF serum level is a risk factor for severe reperfusion edema after lung transplantation K. Krenn, S. Taghavi, W. Klepetko, S. Aharinejad (Vienna, Austria)
| |